The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

Jonathan E. Brammer, MD, discusses the role of minimal residual disease and transplant in acute lymphoblastic leukemia, as well as the introduction of CAR T-cell therapy and other novel agents to the armamentarium.

Alice S. Mims, MD, discusses up front molecular profiling in patients with newly diagnosed acute myeloid leukemia.

Maria Chaudhry, MBBS, discusses unmet needs in relapsed/refractory multiple myeloma.

Jennifer A. Woyach, MD, discusses the evolving treatment paradigm and sequencing challenges in chronic lymphocytic leukemia.

David O’Malley, MD, discusses remaining questions in the ovarian cancer field.

Maria Chaudhry, MBBS, discusses recent and ongoing research in newly diagnosed and relapsed/refractory multiple myeloma.

Maria Chaudhry, MBBS, discusses the use of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone in transplant-ineligible patients with multiple myeloma.

Jennifer Woyach, MD, discusses the results of the ELEVATE-TN trial in patients with treatment-naïve chronic lymphocytic leukemia.

Jennifer Woyach, MD, discusses frontline treatment options for patients with chronic lymphocytic leukemia.

OncLive interviewed experts at the State of the Science Summits™ in December 2019 on what the biggest advances in oncology were in 2019.

Casey M. Cosgrove, MD, discusses later-line treatments in ovarian cancer and ongoing research.

John Hays, MD, PhD, discusses the potential for PARP inhibitor combinations in patients with ovarian cancer.

Ritu Salani, MD, discusses considerations for neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.

John Hays, MD, PhD, discusses ongoing research with immunotherapy in ovarian cancer, challenges with determining predictive biomarkers of response, and promising emerging modalities.

Larry J. Copeland, MD, discusses how therapy for patients with ovarian cancer has evolved in recent years.

Ritu Salani, MD, discusses the potential of targeted therapy and immunotherapy in cervical cancer.

Experts from The Ohio State University and Allegheny Health Network discuss the exciting research being conducted at their institutions.

Ritu Salani, MD, discusses the evolution of up-front chemotherapy, as well as the roles of primary debulking surgery and neoadjuvant chemotherapy in ovarian cancer.

David O’Malley, MD, discusses clinical trials in ovarian cancer and others under investigation.

Floor J. Backes, MD, discusses the safety profile from a phase I study looking at lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

Casey M. Cosgrove, MD, discusses factors to consider when selecting a PARP inhibitor as maintenance therapy in advanced ovarian cancer.

Leigha Senter, MS, LGC, discusses the implications of identifying genes beyond BRCA1/2 in women with ovarian cancer.

Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, discusses treatment selection with PARP inhibitors in ovarian cancer.

Jeffrey M. Fowler, MD, discusses factors used to determine whether a patient with advanced ovarian cancer is eligible for primary cytoreductive surgery.

David O’Malley, MD, discusses the toxicities associated with PARP inhibitors in ovarian cancer.

Floor J. Backes, MD, discusses the next steps regarding a phase I trial investigating lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

Floor J. Backes, MD, discusses the rationale and results from a phase I study exploring lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

David Bond, MD, addresses the ongoing challenge of second primary neoplasia in chronic lymphocytic leukemia.

David A. Bond, MD, assistant professor, The Ohio State University, discusses the high rates of second cancers in both treatment-naïve and pretreated patients with chronic lymphocytic leukemia who received BTK inhibitors.

The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute announced formation of the Pelotonia Institute for Immuno-Oncology, a comprehensive bench-to-bedside research initiative focused on harnessing the body’s immune system to fight cancer at all levels—from prevention to treatment and survivorship.